BGMS

Business Context and Reporting Period

Company: Cyclacel Pharmaceuticals, Inc. (formerly Xcyte Therapies, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2006
Business Overview: A development-stage biopharmaceutical company focused on discovering and developing mechanism-targeted drugs for cancer and other serious disorders. The company operates research facilities in Short Hills, NJ; Dundee, Scotland; and Cambridge, England.

Material Transaction: On March 27, 2006, the company completed a reverse acquisition of Cyclacel Limited (a subsidiary of Cyclacel Group plc). The transaction was accounted for as a reverse merger, with Cyclacel Limited deemed the accounting acquirer. Concurrently, the company sold its T-cell expansion technology ("Xcellerate Process") to Invitrogen Corporation for $5 million.

Key Financial Metrics

Liquidity: As of March 31, 2006, the company held $30.6 million in cash, cash equivalents, and short-term investments. This represents a significant increase from the prior year, primarily driven by the cash and investments assumed in the reverse merger transaction.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased to $151,000 from $56,000 in the prior year, driven by collaboration and grant revenue.
• Expense Surge: Operating expenses increased 94% to $11.9 million. The primary driver was a $6.97 million stock-based compensation charge resulting from the adoption of SFAS 123R and the acceleration of option vesting due to the reverse merger.
• Net Loss Expansion: Net loss applicable to ordinary shareholders increased to $14.2 million from $8.3 million, largely due to the non-cash stock-based compensation and dividends on preferred ordinary shares.
• Balance Sheet Transformation: Total assets doubled to $38.1 million, and total stockholders' equity increased to $25.4 million, reflecting the assets acquired in the reverse merger and the issuance of new equity.
• Debt Reduction: Amounts due to the former parent company (Cyclacel Group plc) decreased from $10.5 million to $1.2 million following the liquidation of the parent and waiver of most intercompany balances.

Guidance, Outlook, and Risks

Outlook and Capital Resources: Management anticipates that current cash, investments, and proceeds from a subsequent private placement (closed May 1, 2006, raising ~$45.3 million) will fund operations through the second quarter of 2008. The company expects to continue incurring substantial operating losses as it advances clinical trials for lead candidates seliciclib, sapacitabine, and CYC116.

Key Risks and Contingencies:

• Development Risk: No products are currently approved for sale; success depends on clinical trial results and regulatory approvals (FDA/EMA).
• Financial Risk: The company has an accumulated deficit of $120.4 million and requires substantial additional capital to continue operations.
• Derivative Liability: A $1.8 million derivative liability exists related to the dividend make-whole feature of convertible preferred stock, which fluctuates with fair value.
• Restructuring Liability: The company recognized a $2.7 million restructuring charge related to a leased manufacturing facility in Bothell, WA, which was discontinued.
• Intellectual Property: Reliance on licensed IP (e.g., from CNRS/Institut Curie and Sankyo) creates risks regarding license termination or infringement claims.

Investor Verification Checklist

• Reverse Merger Accounting: Verify the pro forma financial impact of the reverse acquisition of Cyclacel Limited and the treatment of historical results.
• Stock-Based Compensation: Confirm the $6.97 million expense related to SFAS 123R adoption and option acceleration is non-cash and understand its impact on future burn rates.
• Cash Runway: Validate the sufficiency of the $30.6 million cash balance plus the $45.3 million private placement proceeds to fund operations through 2008.
• Derivative Liability: Monitor the $1.8 million derivative liability associated with preferred stock, as fair value changes will impact future earnings.
• Clinical Milestones: Track progress of Phase II trials for seliciclib and Phase I/II trials for sapacitabine and CYC116, as these are critical for future revenue generation.
• Restructuring Costs: Review the status of the Bothell facility lease and potential sublease income assumptions affecting the $2.7 million liability.